Who are RSI succinylcholine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rocuronium, Tracrium Preservative Free, sufficient dose of rocuronium, Curare (Atracurium), Rocuronium Injectable Solution, Atracurium, TBW.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rsi-succinylcholine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

RSI succinylcholine — Competitive Intelligence Brief

RSI succinylcholine (RSI succinylcholine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Depolarizing neuromuscular blocking agent. Area: Anesthesia.

marketed Depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor (neuromuscular junction) Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

RSI succinylcholine (RSI succinylcholine) — The University of Texas Health Science Center, Houston. Succinylcholine is a depolarizing neuromuscular blocking agent that binds to acetylcholine receptors at the neuromuscular junction, causing sustained depolarization and muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RSI succinylcholine TARGET	RSI succinylcholine	The University of Texas Health Science Center, Houston	marketed	Depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor (neuromuscular junction)
Rocuronium	Rocuronium Bromide	Merck & Co.	marketed	Nondepolarizing neuromuscular blocking agent	Cholinergic receptors at the motor end-plate	1994-01-01
Tracrium Preservative Free	Atracurium Besylate	Pfizer Inc.	marketed	Nondepolarizing neuromuscular blocking agent	Cholinergic receptor sites on motor end-plate	1983-01-01
sufficient dose of rocuronium	sufficient dose of rocuronium	Korea University Guro Hospital	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Curare (Atracurium)	Curare (Atracurium)	CHU de Reims	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor (neuromuscular junction)
Rocuronium Injectable Solution	Rocuronium Injectable Solution	Federal University of São Paulo	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Atracurium, TBW	Atracurium, TBW	St. Antonius Hospital	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2039-07-22 — Rocuronium · 11998605 · Formulation · US

Sponsor landscape (Depolarizing neuromuscular blocking agent class)

The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RSI succinylcholine — Competitive Intelligence Brief. https://druglandscape.com/ci/rsi-succinylcholine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab